WO2010088000A3 - Composés antifibrotiques et leurs utilisations - Google Patents
Composés antifibrotiques et leurs utilisations Download PDFInfo
- Publication number
- WO2010088000A3 WO2010088000A3 PCT/US2010/000287 US2010000287W WO2010088000A3 WO 2010088000 A3 WO2010088000 A3 WO 2010088000A3 US 2010000287 W US2010000287 W US 2010000287W WO 2010088000 A3 WO2010088000 A3 WO 2010088000A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compounds
- antifibrotic compounds
- antifibrotic
- subclasses
- classes
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
Abstract
La présente invention concerne des composés ayant les formules (I), (II) et (III) : F et leurs dérivés pharmaceutiquement acceptables, comme il est décrit généralement et par classes et sous-classes ici, et elle concerne en outre des compositions pharmaceutiques les contenant, et des procédés pour les utiliser pour le traitement de l'un quelconque de nombreux états et maladies impliquant une fibrose et pour lesquels une activité antifibrotique est bénéfique.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US20661509P | 2009-02-02 | 2009-02-02 | |
US61/206,615 | 2009-02-02 | ||
US21474409P | 2009-04-28 | 2009-04-28 | |
US61/214,744 | 2009-04-28 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2010088000A2 WO2010088000A2 (fr) | 2010-08-05 |
WO2010088000A3 true WO2010088000A3 (fr) | 2011-04-07 |
Family
ID=42396268
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2010/000287 WO2010088000A2 (fr) | 2009-02-02 | 2010-02-02 | Composés antifibrotiques et leurs utilisations |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2010088000A2 (fr) |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8883819B2 (en) | 2011-09-01 | 2014-11-11 | Irm Llc | Bicyclic heterocycle derivatives for the treatment of pulmonary arterial hypertension |
EA037918B1 (ru) | 2011-12-21 | 2021-06-07 | Новира Терапьютикс, Инк. | Противовирусные агенты против гепатита в |
CN104136436B (zh) | 2012-01-26 | 2019-01-01 | 安贞生物医学公司 | 抗纤维化的化合物及其用途 |
SG10201605291WA (en) | 2012-08-28 | 2016-08-30 | Janssen Sciences Ireland Uc | Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis b |
HUE034820T2 (en) | 2013-02-28 | 2018-02-28 | Janssen Sciences Ireland Uc | Sulphamoyl arylamides and their use as medicaments for the treatment of hepatitis B |
US9073921B2 (en) | 2013-03-01 | 2015-07-07 | Novartis Ag | Salt forms of bicyclic heterocyclic derivatives |
US8993771B2 (en) | 2013-03-12 | 2015-03-31 | Novira Therapeutics, Inc. | Hepatitis B antiviral agents |
BR112015025052A2 (pt) | 2013-04-03 | 2021-07-06 | Janssen Sciences Ireland Uc | derivados de n-fenil-carboxamida e o seu uso como medicamentos para o tratamento da hepatite b |
JO3603B1 (ar) | 2013-05-17 | 2020-07-05 | Janssen Sciences Ireland Uc | مشتقات سلفامويل بيرولاميد واستخدامها كادوية لمعالجة التهاب الكبد نوع بي |
AP2015008968A0 (en) | 2013-07-25 | 2015-12-31 | Janssen Sciences Ireland Uc | Glyoxamide substituted pyrrolamide derivatives andthe use thereof as medicaments for the treatment of hepatitis b |
EP3060547B1 (fr) | 2013-10-23 | 2017-10-11 | Janssen Sciences Ireland UC | Dérivés de carboxamide et leur utilisation comme médicaments pour le traitement de l'hépatite b |
US9181288B2 (en) | 2014-01-16 | 2015-11-10 | Novira Therapeutics, Inc. | Azepane derivatives and methods of treating hepatitis B infections |
US10392349B2 (en) | 2014-01-16 | 2019-08-27 | Novira Therapeutics, Inc. | Azepane derivatives and methods of treating hepatitis B infections |
US9169212B2 (en) | 2014-01-16 | 2015-10-27 | Novira Therapeutics, Inc. | Azepane derivatives and methods of treating hepatitis B infections |
ES2792848T3 (es) | 2014-02-05 | 2020-11-12 | Novira Therapeutics Inc | Politerapia para el tratamiento de infecciones por VHB |
EA035848B1 (ru) | 2014-02-06 | 2020-08-20 | Янссен Сайенсиз Айрлэнд Юси | Производные сульфамоилпирроламида и их применение в качестве медикаментов для лечения гепатита b |
US9400280B2 (en) | 2014-03-27 | 2016-07-26 | Novira Therapeutics, Inc. | Piperidine derivatives and methods of treating hepatitis B infections |
EP3271019A1 (fr) | 2015-03-19 | 2018-01-24 | Novira Therapeutics Inc. | Dérivés d'azocane et d'azonane, et méthodes de traitement d'infections provoquées par le virus de l'hépatite b |
US10875876B2 (en) | 2015-07-02 | 2020-12-29 | Janssen Sciences Ireland Uc | Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis B |
WO2017059059A1 (fr) | 2015-09-29 | 2017-04-06 | Novira Therapeutics, Inc. | Formes cristallines d'un agent antiviral de l'hépatite b |
SG11201808949SA (en) | 2016-04-15 | 2018-11-29 | Novira Therapeutics Inc | Combinations and methods comprising a capsid assembly inhibitor |
US10973801B2 (en) | 2018-03-14 | 2021-04-13 | Janssen Sciences Ireland Unlimited Company | Capsid assembly modulator dosing regimen |
TW202045499A (zh) | 2019-02-22 | 2020-12-16 | 愛爾蘭商健生科學愛爾蘭無限公司 | 用於治療hbv感染或hbv誘發疾病之醯胺衍生物 |
CA3132554A1 (fr) | 2019-05-06 | 2020-11-12 | Bart Rudolf Romanie Kesteleyn | Derives d'amide utiles dans le traitement d'une infection par le virus de l'hepatite b ou de maladies induites par le virus de l'hepatite b |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004063330A2 (fr) * | 2003-01-06 | 2004-07-29 | Osi Pharmaceuticals, Inc. | Composes de (2-carboxamido) (3-amino) thiophene |
US20050154014A1 (en) * | 2003-01-06 | 2005-07-14 | Jason Bloxham | (2-carboxamido)(3-amino) thiophene compounds |
US20060074082A1 (en) * | 2004-09-17 | 2006-04-06 | Arlindo Castelhano | (Arylamidoaryl)cyanoguanidine compounds |
WO2006070878A1 (fr) * | 2004-12-28 | 2006-07-06 | Astellas Pharma Inc. | Derive d'acide carboxylique ou sel de ce derive |
-
2010
- 2010-02-02 WO PCT/US2010/000287 patent/WO2010088000A2/fr active Application Filing
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004063330A2 (fr) * | 2003-01-06 | 2004-07-29 | Osi Pharmaceuticals, Inc. | Composes de (2-carboxamido) (3-amino) thiophene |
US20050154014A1 (en) * | 2003-01-06 | 2005-07-14 | Jason Bloxham | (2-carboxamido)(3-amino) thiophene compounds |
US20060074082A1 (en) * | 2004-09-17 | 2006-04-06 | Arlindo Castelhano | (Arylamidoaryl)cyanoguanidine compounds |
WO2006070878A1 (fr) * | 2004-12-28 | 2006-07-06 | Astellas Pharma Inc. | Derive d'acide carboxylique ou sel de ce derive |
Also Published As
Publication number | Publication date |
---|---|
WO2010088000A2 (fr) | 2010-08-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2010088000A3 (fr) | Composés antifibrotiques et leurs utilisations | |
WO2011153192A3 (fr) | Inhibiteurs des cytochromes p450 et leurs utilisations | |
WO2011127333A3 (fr) | Composés pour le traitement d'une maladie, pour l'administration, et pour des compositions pharmaceutiques | |
WO2013112959A8 (fr) | Composés antifibrotiques et leurs utilisations | |
WO2010084115A3 (fr) | Agents antiviraux | |
MX2011012122A (es) | Derivados de tiofeno. | |
WO2012116290A3 (fr) | Stéroïdes neuroactifs substitués par 17(20)-z-vinylcyano, promédicaments de ceux-ci et procédés de traitement les utilisant | |
AU2012243329A8 (en) | 5-substituted iminothiazines and their mono-and dioxides as BACE inhibitors,compositions,and their use | |
WO2007127635A3 (fr) | Dérivés de dicéto-pipérazine et pipéridine en tant qu'agents antiviraux | |
WO2008000483A3 (fr) | Composés organiques | |
WO2009109618A3 (fr) | Nouveaux dérivés de 1-benzyl-3-hydroxyméthylindazole et leur utilisation dans le traitement des maladies basées sur l’expression de mcp-1, cx3cr1 et p40 | |
GEP20186880B (en) | 2-amino-3, 5, 5-trifluoro-3, 4, 5, 6-tetrahydropyridines as bace1 inhibitors for treatment of alzheimer's disease | |
WO2009109616A8 (fr) | Nouveaux dérivés de 1-benzyl-3-hydroxyméthylindazole et leur utilisation dans le traitement des maladies basées sur l'expression de mcp-1, cx3cr1 et p40 | |
MX2012000275A (es) | Antagonista de bomba de acido para el tratamiento de enfermedades involucradas en la motilidad gastrointestinal anormal. | |
MX2009013501A (es) | Compuestos piperidinicos y sus usos. | |
WO2009109654A8 (fr) | Nouveaux dérivés de 1-benzyl-3-hydroxyméthylindazole et leur utilisation dans le traitement des maladies basées sur l’expression de mcp-1 et cx3cr1 | |
WO2009041663A1 (fr) | Agent destiné à la prévention et/ou au traitement de maladies cutanées | |
WO2011097946A8 (fr) | Composés oxazolidinone contenant deux cycles fusionnés, procédé de préparation associé et utilisation associée | |
WO2012135615A3 (fr) | Enopeptines, utilisations de celles-ci, et procédés de synthèse de celles-ci | |
WO2012168885A9 (fr) | Bisacodyle et ses analogues en tant que médicaments pour le traitement du cancer | |
MX362830B (es) | Agente terapeutico o profilactico para enfermedades del tracto biliar. | |
WO2012128582A3 (fr) | Composé capable d'inhiber la 11-bêta-hydroxystéroïde déshydrogénase de type 1 humaine et composition pharmaceutique en contenant | |
MX2012013879A (es) | Derivados de hidroxipiridona, composiciones farmceuticas de los mismos y su uso terapeutico para tratar enfermedades proliferativas. | |
WO2011009714A3 (fr) | Dérivés de sel de benzoquinolizinium comme agents anti-cancéreux | |
WO2010121675A3 (fr) | Thiazolyl-benzimidazoles |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 10736165 Country of ref document: EP Kind code of ref document: A2 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 10736165 Country of ref document: EP Kind code of ref document: A2 |